iSpecimen

iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in July 2009 and is headquartered in Lexington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iSpecimen reports improved Q1 performance, eyes growth opportunities ahead

iSpecimen's Q1 2024 earnings call highlighted improved financial performance through cost management and sales growth initiatives.
While facing challenges of lower specimen counts, the company showcased strengths in pricing power, supply efficiency, and cash position.
Opportunities lie in leveraging successful programs, exploring new markets, investing in technology, and strategic partnerships for future growth.
Overall, iSpecimen's positive outlook on operational advancements signals a commitment to sustainable growth and innovation in the healthcare sector.

iSpecimen beats revenue targets, strengthens operations for future growth

iSpecimen delivered strong Q2 2024 results, surpassing revenue targets and improving operational efficiency. The company's strategic initiatives to reduce costs, optimize workforce, and enhance supplier relationships are driving growth. While challenges like funding needs persist, iSpecimen is well-positioned for future opportunities in the healthcare specimen sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

BioVie Inc

Galera Therapeutics

23andMe

Singular Genomics Systems

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)

Program to Provide Cancer Researchers with Direct Access to Highly Sought Donor Tumor Tissue Samples Virtual Inventory Comprised of Formalin-Fixed, Paraffin-Embedded (FFPE) Samples Screened for Mutations LEXINGTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the launch of a new program that gives researchers consistent and direct access to mutation-characterized formalin-fixed, paraffin-embedded (“FFPE”) cancer tumor tissues, relieving a major bottleneck in cancer research.

iSpecimen Launches New Virtual Cancer Sequencing Procurement Program

New Capabilities Enable Platform to Efficiently Collect and Store Most Up-to-Date Data from Providers and Facilitate Automated, Instant Matchmaking for Researcher Requests New Capabilities Enable Platform to Efficiently Collect and Store Most Up-to-Date Data from Providers and Facilitate Automated, Instant Matchmaking for Researcher Requests

iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers

Company Continues to Enhance the Biospecimen Procurement Process and Provide Increasingly Robust Specimen and Patient Data Company Continues to Enhance the Biospecimen Procurement Process and Provide Increasingly Robust Specimen and Patient Data

iSpecimen Introduces New Marketplace Functionality to Streamline Access to Clinical Remnant Samples for Researchers

iSpecimen Inc. (NASDAQ:ISPC ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Phil Carlson - Investor Relations, KCSA Strategic Communications Tracy Curley - Chief Executive Officer and Chief Financial Officer Eric Langlois - Chief Revenue Officer Evan Cox - Vice President of Product Management Conference Call Participants Operator Good day, everyone, and welcome to iSpecimen's Second Quarter 2023 Results Conference Call. At this time participants are in a listen-only mode.

iSpecimen Inc. (ISPC) Q2 2023 Earnings Call Transcript

LEXINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2023.

iSpecimen Reports Second Quarter 2023 Financial and Operating Results

LEXINGTON, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2023 before the market opens on Wednesday, August 2, 2023.

iSpecimen to Report Second Quarter 2023 Results on August 2, 2023

Network's Expansion Across the U.S. and Europe Aims to Advance Translational Genomics Research Network's Expansion Across the U.S. and Europe Aims to Advance Translational Genomics Research

Thirteen New Biospecimen Suppliers Added to iSpecimen's Proprietary Provider Network

LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group LLC (“Maxim”) and M-Vest, a division of Maxim, on Thursday, June 1, 2023.

iSpecimen to Participate in Maxim's Healthcare IT Virtual Conference on June 1, 2023

iSpecimen Inc. (NASDAQ:ISPC ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Tracy Curley - Chief Executive Officer Benjamin Beilak - Chief Information Officer Eric Langlois - Chief Revenue Officer Conference Call Participants Matt Hewitt - Craig Hallum Capital Group Operator Good morning, and welcome to iSpecimen First Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note that this event is being recorded.

iSpecimen Inc. (ISPC) Q1 2023 Earnings Call Transcript

LEXINGTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2023.

iSpecimen Reports First Quarter 2023 Results

LEXINGTON, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Aegis Conference to be held virtually on May 2-4, 2023.

iSpecimen to Participate in the Aegis Virtual Conference on May 4, 2023

LEXINGTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the first quarter ended March 31, 2023 before the market opens on Thursday, May 4, 2023.

iSpecimen to Report First Quarter 2023 Results on May 4, 2023

iSpecimen Inc. (NASDAQ:ISPC ) Q4 2022 Earnings Call Transcript March 14, 2023 8:30 AM ET Company Participants Allison Soss - Investor Relations-KCSA Strategic Communications Tracy Curley - Chief Executive Officer Benjamin Bielak - Chief Information Officer Eric Langlois - Chief Revenue Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Allen Klee - Maxim Group Operator Good day, everyone and welcome to iSpecimen's Full Year 2022 Conference Call. At this time, participants will be in a listen-only mode.

iSpecimen Inc. (ISPC) Q4 2022 Earnings Call Transcript

iSpecimen Inc said its revenue jumped 28% year-over-year in the fourth quarter as it made quick improvements to supplier utilization rates to boost overall fulfillment efficiency. For the period ended December 31, 2022, the Lexington, Massachusetts-based company reported revenue of $3.2 million, compared to $2.5 million in 4Q  2021.

iSpecimen sees 4Q revenue rise by 28% as it focuses on its supplier network and fulfillment efficiency

- Reported Record Quarterly Revenue of $3.2 Million, Up 28% Year-Over-Year - - Reported Record Quarterly Revenue of $3.2 Million, Up 28% Year-Over-Year -

iSpecimen Reports Full Year 2022 Results

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2022, before the markets open on Tuesday, March 14, 2023.

iSpecimen to Report Fourth Quarter and Full Year 2022 Results on March 14, 2023

iSpecimen Strategically Grows its Proprietary Marketplace Platform with Seven New Biospecimen Sample Providers Across the U.S. and Europe iSpecimen Strategically Grows its Proprietary Marketplace Platform with Seven New Biospecimen Sample Providers Across the U.S. and Europe

iSpecimen Expands Biospecimen Provider Network

Mr. Langlois Led iSpecimen to 3,000 Percent Revenue Growth During His Tenure as the Company's Former SVP of Sales and Business Development Mr. Langlois Led iSpecimen to 3,000 Percent Revenue Growth During His Tenure as the Company's Former SVP of Sales and Business Development

iSpecimen Appoints Eric Langlois as Chief Revenue Officer

LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Sequire Biotechnology Conference to be held virtually on Thursday, February 2, 2023.

iSpecimen to Participate in the Sequire Biotechnology Conference on February 2, 2023

LEXINGTON, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group and M-Vest on Wednesday, January 25, 2023.

iSpecimen to Participate in Maxim's Healthcare IT Virtual Conference on January 25, 2023

Previously Appointed Interim CEO in September 2022 Previously Appointed Interim CEO in September 2022

iSpecimen Names Tracy Curley as Chief Executive Officer

Sought-After Strategic Advisor Brings Expertise in Mergers and Acquisitions, Restructuring and Governance to iSpecimen Sought-After Strategic Advisor Brings Expertise in Mergers and Acquisitions, Restructuring and Governance to iSpecimen

iSpecimen Appoints Joseph J. Basile to Board of Directors

iSpecimen Inc. (NASDAQ:ISPC ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Allison Soss - IR Tracy Curley - Interim-CEO and CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Operator Good day, everyone, and welcome to the iSpecimen Third Quarter 2022 Conference Call. [Operator Instructions] This conference call is being recorded.

iSpecimen Inc. (ISPC) Q3 2022 Earnings Call Transcript

- Reported Revenue of $2.6 Million, Comprised Of A Record 88% Non-COVID Revenue - - Reported Revenue of $2.6 Million, Comprised Of A Record 88% Non-COVID Revenue -

News for iSpecimen Stock (ISPC)